1. Medtech Insight

CMS Lessens Lab Test Cuts, Finalizes Revaluation Proposal In Physician Fee Schedule

In the final 2014 physician fee schedule rule, CMS scaled back cuts to independent labs from 26 percent to 5 percent. But it moved ahead with its proposal to update individual lab payments based on technological changes, a move that might lead to reductions over the long term.

Diagnostic laboratories and test makers can breathe easier in the near-term following CMS’ decision to scale back planned 2014 payment cuts to independent laboratories in the latest physician fee schedule. But the agency is moving forward with a longer-term wholesale review and planned revision of laboratory payments that is likely to keep the diagnostics community anxious.

Under the final 2014 physician fee schedule regulation, released by CMS on Nov. 27, the agency is cutting...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Policy & Regulation

More from Medtech Insight

US FDA Unveils Plans To Consolidate Support Services

 
• By Derrick Gingery and Sue Sutter

Commissioner Martin Makary told staff that plans are being developed to centralize HR, IT, travel and other functions, which were heavily impacted by the 1 April reduction-in-force.

A Year After Exiting The Ventilator Market, Medtronic Recalls Thousands Of Newport Devices

 
• By Brian Bossetta

After two serious injuries and one death linked to some of its ventilators, Medtronic has recalled the devices and asked customers to stop using them and find alternative means. The action comes more than a year after the company left the market.

‘UK Must Put Adoption On A Par With Innovation’

 
• By Ashley Yeo

Market access concerns dominated at the annual BioWales In London event, where AstraZeneca set out industry’s priorities and the UK Office for Life Sciences struck an optimistic tone about how the UK will lastingly improve uptake of innovation.